Drugs / Tesaglitazar
Trials 17 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials | ||||||
| Phase 2 | NCT00263965 | Aug 2005 → Jul 2006 | type 2 diabetes mellitus | AstraZeneca | Terminated | No outcome recorded |
| Phase 2 | NCT00229684 | Sep 2004 → Jun 2006 | type 2 diabetes mellitus | AstraZeneca | Terminated | No outcome recorded |
| Phase 2 | NCT00261417 | May 2004 → Oct 2005 | type 2 diabetes mellitus | AstraZeneca | Terminated | No outcome recorded |
| Phase 2 | NCT00280865 | Apr 2002 → Jun 2003 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 313 trials | ||||||
| Phase 3 | NCT00300105 | Oct 2005 → Dec 2006 | type 2 diabetes mellitus | AstraZeneca | Terminated | No outcome recorded |
| Phase 3 | NCT00252837 | Apr 2005 → Dec 2006 | type 2 diabetes mellitus | AstraZeneca | Terminated | No outcome recorded |
| Phase 3 | NCT00261352 | Mar 2005 → Dec 2006 | type 2 diabetes mellitus | AstraZeneca | Terminated | No outcome recorded |
| Phase 3 | NCT00226330 | Mar 2005 → Dec 2006 | type 2 diabetes mellitus | AstraZeneca | Terminated | No outcome recorded |
| Phase 3 | NCT00252876 | Mar 2005 → Jan 2007 | type 2 diabetes mellitus | AstraZeneca | Terminated | No outcome recorded |
| Phase 3 | NCT00229710 | Feb 2005 → Dec 2006 | type 2 diabetes mellitus | AstraZeneca | Terminated | No outcome recorded |
| Phase 3 | NCT00255541 | Sep 2004 → Dec 2006 | type 2 diabetes mellitus | AstraZeneca | Terminated | No outcome recorded |
| Phase 3 | NCT00252772 | Sep 2004 → Nov 2006 | type 2 diabetes mellitus | AstraZeneca | Terminated | No outcome recorded |
| Phase 3 | NCT00214565 | Aug 2004 → Oct 2006 | type 2 diabetes mellitus | AstraZeneca | Terminated | No outcome recorded |
| Phase 3 | NCT00214591 | Aug 2004 → Dec 2006 | type 2 diabetes mellitus | AstraZeneca | Terminated | No outcome recorded |
| Phase 3 | NCT00242372 | Aug 2004 → Mar 2006 | type 2 diabetes mellitus | AstraZeneca | Terminated | No outcome recorded |
| Phase 3 | NCT00251940 | Jul 2004 → Mar 2006 | type 2 diabetes mellitus | AstraZeneca | Terminated | No outcome recorded |
| Phase 3 | NCT00251953 | Jul 2004 → Mar 2006 | type 2 diabetes mellitus | AstraZeneca | Terminated | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tesaglitazar | “A 52-wk Randomised, Double-Blind, Parallel-Group, Multi-Centre, Active-Controlled (Metformin) Study to Evaluate the Efficacy, Safety & Tolerability of Tesaglitazar Therapy When...” NCT00214591 ↗16“This is a 24-week randomized, double-blind, multi-center, active-controlled (pioglitazone) study of tesaglitazar (0.5 mg and 1 mg) in patients with type 2 diabetes” NCT00214565 ↗ |
| Known as | AR-H-039242 | ChEMBL registry synonym — accepted as the source's own label CHEMBL282686 ↗ |
| Known as | AR-H039242XX | ChEMBL registry synonym — accepted as the source's own label CHEMBL282686 ↗ |
| Known as | AZ-242 | ChEMBL registry synonym — accepted as the source's own label CHEMBL282686 ↗ |
| Known as | BR-44608 | ChEMBL registry synonym — accepted as the source's own label CHEMBL282686 ↗ |
| Known as | Galida | ChEMBL registry synonym — accepted as the source's own label CHEMBL282686 ↗ |
| Action | Activate | “dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist tesaglitazar” PMID 17166340 ↗ Dec 20062“Peroxisome proliferator-activated receptor gamma agonist” CHEMBL282686 ↗ “Peroxisome proliferator-activated receptor alpha agonist” CHEMBL282686 ↗ |
| Modality | Small molecule | — CHEMBL282686 ↗ |
| Route | Oral | “oral tesaglitazar” NCT00226330 ↗ |
| Target | PPARA | “Peroxisome proliferator-activated receptor alpha agonist” CHEMBL282686 ↗ |
| Target | PPARG | “Peroxisome proliferator-activated receptor gamma agonist” CHEMBL282686 ↗ |